PRNewsWire
03 Aug 2026, 13:54 UTC · 58m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities fraud class action lawsuit alleging it engaged in 'channel stuffing' to inflate 2025 revenue growth. — Allegations of financial manipulation and artificial revenue inflation typically lead to severe loss of investor trust and potential regulatory penalties.
-0.80A Culper Research report claims ADMA's reported 20% revenue growth in 2025 was actually a 3% decline when excluding alleged channel stuffing. — The discrepancy between reported growth and real growth suggests a fundamental failure in the company's organic growth trajectory.
-0.70ADMA shares experienced a sharp decline of approximately 31% over two trading days in March 2026 following the publication of the Culper Research report. — The immediate and significant price drop confirms the market's negative reaction to the fraud allegations.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and inflated revenue growth.
The company is the subject of a class action lawsuit announced by Berger Montague.
The company is mentioned as being under investigation for potential legal claims by a plaintiffs' law firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
3h ago
